In this trial, “high risk” was defined as “patients with four or more positive pathologic axillary lymph nodes or 1–3 positive axillary lymph nodes and at least one of the following: tumor size > 5 cm, histological grade 3, or centrally assessed Ki-67 expression > 20%” [18]. The gene discussed is MKI67; the disease is neoplasm.